AMRX

NASD Amneal Pharmaceuticals, Inc. Class A

Oct 27, 2026 · 11:36 PM ET EOD Market Closed

$21.44 ↑ +0.00 (+0.00%) Trading Up from the previous close of $21.44, $0.02 below the day’s high of $21.46

YTD change: +70.16%
vs 20-day SMA: +7.53%
vs 200-day SMA: +37.65%

Price ranges

Previous day

$20.54 $21.14

open $20.63 close $21.02

+$0.39 (+1.89%)

Today

$20.93 $21.46

open $20.93 now $21.44

+$0.51 (+2.44%)

Past week

$19.31 $21.14

from $19.36 now $21.44

+$2.08 (+10.74%)

Past month

$18.79 $21.14

from $20.50 now $21.44

+$0.94 (+4.59%)

This year

$11.71 $21.46

from $12.60 now $21.44

+$8.84 (+70.16%)

Price & Performance

+8.87 (+70.56%) / 6M

Signals & Sentiment

Momentum, market sentiment, and recent alerts

Very Good

The stock is 12.4% away from all-time highs of $24.48
AMRX is up 70% since the beginning of the year
AMRX is up 109% over the past 12 months
AMRX is up 5% over the past 1 month
8% of all AMRX investors are betting against AMRX

AMRX reads very good: price sits above both the 20- and 200-day averages, the 12-month move is +109.2%.

Financial Strength

Earnings, valuation, and balance sheet

Earnings

Profitable Yes

EPS $0.3

Earnings momentum -27.1% Quarterly EPS growth

Quarterly change -27.1%

Valuation

P/E ratio 41.59

Enterprise value $9.6B

Beta 0.65

Balance sheet & scale

Income$157.4K

Revenue$3.1B

Cash$136.3M

Debt$2.8M

Income / Debt 0.06×

Company & Peers

Company profile and competitor comparison

Company profile

ExchangeNASD

Sector Manufacturing

Sub Sector Chemical Manufacturing

Market cap $6.8B

Amneal Pharmaceuticals, Inc. is a medicine company, which engages in the provision of pharmaceuticals. Its product portfolio includes generics, specialty, biosciences, and product catalog. It operates through the following segments: Generics, Specialty, and AvKARE. The Generics segment relates to oral solids, powders, liquids, sterile injectables, nasal sprays, inhalation and respiratory products, biosimilar products, ophthalmics, films, and transdermal patches and topicals. The Specialty segment refers to the development, promotion, sale, and distribution of proprietary branded pharmaceutical products. The AvKARE segment provides pharmaceuticals, medical, and surgical products and services to governmental agencies. The company was founded by Chirag K. Patel and Chintu Patel in 2002 and is headquartered in Bridgewater, NJ.

Competitor comparison

Ticker	Company	Price	Change
LLY	Eli Lilly and Company	$1,281.91	+0.22%
JNJ	Johnson & Johnson	$268.73	+0.91%
ABBV	AbbVie, Inc.	$286.39	-0.12%
MRK	Merck & Co., Inc.	$141.82	+0.86%
RHHBY	Roche Holding Ltd Sponsored ADR	$60.37	+0.65%

You looked up one stock
Trade Ideas watches them all

Real-time scanning and AI-generated signals across the entire market.

See plans TI Pro Download

Prices and alerts are delayed by at least 20 minutes. Chart history reflects daily closing prices. Information is provided for research purposes only and is not investment advice.